GLP-1RA reduces kidney outcomes in people with T2D and CKD
In the FLOW trial, treatment with semaglutide reduced the risk of the primary composite endpoint of kidney disease progression, or death from kidney disease or CVD by 24% in people with T2D and CKD.
The headline results from the FLOW trial have been announced. Treatment with semaglutide 1.0 mg reduced the primary composite endpoint of kidney disease progression, or death from kidney disease or CVD by 24% in persons with T2D and CKD compared with placebo. The CKD components as well as the cardiovascular components of the primary endpoint contributed to the risk reduction. The superiority of semaglutide versus placebo was further confirmed for key secondary endpoints. The FLOW trial was stopped early after meeting the efficacy criteria in the interim analysis.
A similar safety and tolerance profile of semaglutide 1.0 mg was observed as previously reported in other trials with semaglutide 1.0 mg.
FLOW was a randomized, double-blind, placebo-controlled, superiority trial in which 3533 patients with T2D and CKD were randomized to injectable semaglutide 1.0 mg once weekly or placebo as an adjunct to standard care. The composite primary endpoint consisted of onset of persistent ≥50% reduction in eGFR according to the CKD-EPI equation compared with baseline, onset of persistent eGFR (CKD-EPI) <15 mL/min/1.73 m², initiation of chronic kidney replacement therapy (dialysis or kidney transplantation), death from kidney disease or death from CVD. Confirmatory secondary endpoints were annual rate of change in eGFR (CKD-EPI), MACE (defined as non-fatal MI, non-fatal stroke, cardiovascular death) and all-cause mortality.
The detailed results of the FLOW trial will be presented at a scientific conference later this year.